The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Transplantation, Homologous

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Transplantation, Homologous


Psychiatry related information on Transplantation, Homologous


High impact information on Transplantation, Homologous

  • The underlying science and the prospects for inducing long-lived antigen-specific tolerance in a model of allograft tolerance through CD154 blockade are presented and discussed [8].
  • New forms of therapy directed at IL-2 and IL-15 receptors may be effective against certain neoplastic diseases and autoimmune disorders and in the prevention of allograft rejection [9].
  • Rejection of transplanted tissue allografts results from T-cell recognition of histocompatibility antigens expressed by cells of the donor graft [10].
  • Messenger RNA (mRNA) encoding the cytotoxic proteins perforin and granzyme B and a constitutively expressed cyclophilin B gene were measured with the use of a competitive, quantitative polymerase chain reaction, and the level of expression was correlated with allograft status [11].
  • MPA is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug recently approved for the treatment of allograft rejection [12].

Chemical compound and disease context of Transplantation, Homologous


Biological context of Transplantation, Homologous


Anatomical context of Transplantation, Homologous


Associations of Transplantation, Homologous with chemical compounds


Gene context of Transplantation, Homologous

  • Thus, the FasL signal provided site- and immune-specific protection of islet allografts [33].
  • Signals generated through CD28-B7 and CD40 ligand (CD40L)-CD40 interactions have been shown to be crucial for the induction of long-term allograft survivability [34].
  • Requirement of the chemokine receptor CXCR3 for acute allograft rejection [35].
  • However, though allografts from IP-10(+/+) mice were rejected by day 7, hearts from IP-10(-/-) mice survived long term [36].
  • Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor [37].

Analytical, diagnostic and therapeutic context of Transplantation, Homologous


  1. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. Balfour, H.H., Chace, B.A., Stapleton, J.T., Simmons, R.L., Fryd, D.S. N. Engl. J. Med. (1989) [Pubmed]
  2. Cyclosporine-induced hyperuricemia and gout. Lin, H.Y., Rocher, L.L., McQuillan, M.A., Schmaltz, S., Palella, T.D., Fox, I.H. N. Engl. J. Med. (1989) [Pubmed]
  3. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Tellides, G., Tereb, D.A., Kirkiles-Smith, N.C., Kim, R.W., Wilson, J.H., Schechner, J.S., Lorber, M.I., Pober, J.S. Nature (2000) [Pubmed]
  4. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Palfi, S., Condé, F., Riche, D., Brouillet, E., Dautry, C., Mittoux, V., Chibois, A., Peschanski, M., Hantraye, P. Nat. Med. (1998) [Pubmed]
  5. The multichain interleukin 2 receptor. A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts [clinical reference]. Waldmann, T.A. JAMA (1990) [Pubmed]
  6. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies. Ditzel, H.J., Rosenkilde, M.M., Garred, P., Wang, M., Koefoed, K., Pedersen, C., Burton, D.R., Schwartz, T.W. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  7. Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisone. Lorber, M.I., Flechner, S.M., Van Buren, C.T., Sorensen, K., Kerman, R.H., Kahan, B.D. Am. J. Kidney Dis. (1987) [Pubmed]
  8. CD40/CD154 interactions at the interface of tolerance and immunity. Quezada, S.A., Jarvinen, L.Z., Lind, E.F., Noelle, R.J. Annu. Rev. Immunol. (2004) [Pubmed]
  9. The meandering 45-year odyssey of a clinical immunologist. Waldmann, T.A. Annu. Rev. Immunol. (2003) [Pubmed]
  10. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Rosenberg, A.S., Singer, A. Annu. Rev. Immunol. (1992) [Pubmed]
  11. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. Li, B., Hartono, C., Ding, R., Sharma, V.K., Ramaswamy, R., Qian, B., Serur, D., Mouradian, J., Schwartz, J.E., Suthanthiran, M. N. Engl. J. Med. (2001) [Pubmed]
  12. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Sintchak, M.D., Fleming, M.A., Futer, O., Raybuck, S.A., Chambers, S.P., Caron, P.R., Murcko, M.A., Wilson, K.P. Cell (1996) [Pubmed]
  13. Immunity to Epstein-Barr virus in cyclosporin A-treated renal allograft recipients. Crawford, D.H., Edwards, J.M. Lancet (1982) [Pubmed]
  14. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole. Bradley, P.P., Warden, G.D., Maxwell, J.G., Rothstein, G. Ann. Intern. Med. (1980) [Pubmed]
  15. Cyclosporine A has no direct effect on collagen metabolism by cardiac fibroblasts in vitro. Eleftheriades, E.G., Ferguson, A.G., Samarel, A.M. Circulation (1993) [Pubmed]
  16. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Weissinger, F., Sandmaier, B.M., Maloney, D.G., Bensinger, W.I., Gooley, T., Storb, R. Blood (2001) [Pubmed]
  17. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Werner-Felmayer, G., Werner, E.R., Fuchs, D., Hausen, A., Reibnegger, G., Wachter, H. Cancer Res. (1990) [Pubmed]
  18. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Ito, H., Koefoed, M., Tiyapatanaputi, P., Gromov, K., Goater, J.J., Carmouche, J., Zhang, X., Rubery, P.T., Rabinowitz, J., Samulski, R.J., Nakamura, T., Soballe, K., O'Keefe, R.J., Boyce, B.F., Schwarz, E.M. Nat. Med. (2005) [Pubmed]
  19. H-2 antigen class: effect on mouse islet allograft rejection. Morrow, C.E., Sutherland, D.E., Steffes, M.W., Najarian, J.S., Bach, F.H. Science (1983) [Pubmed]
  20. Stability of renal transplant function with alternate-day corticosteroid therapy. Breitenfield, R.V., Hebert, L.A., Lemann, J., Piering, W.F., Kauffman, H.M., Sampson, D., Kalbfleisch, J., Beres, J.A. JAMA (1980) [Pubmed]
  21. Recipient iNOS but not eNOS deficiency reduces luminal narrowing in tracheal allografts. Minamoto, K., Pinsky, D.J. J. Exp. Med. (2002) [Pubmed]
  22. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. Hall, B.M., Jelbart, M.E., Gurley, K.E., Dorsch, S.E. J. Exp. Med. (1985) [Pubmed]
  23. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. Labarrere, C.A., Pitts, D., Nelson, D.R., Faulk, W.P. N. Engl. J. Med. (1995) [Pubmed]
  24. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Siekierka, J.J., Hung, S.H., Poe, M., Lin, C.S., Sigal, N.H. Nature (1989) [Pubmed]
  25. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Beilke, J.N., Kuhl, N.R., Van Kaer, L., Gill, R.G. Nat. Med. (2005) [Pubmed]
  26. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Madsen, J.C., Superina, R.A., Wood, K.J., Morris, P.J. Nature (1988) [Pubmed]
  27. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Isobe, M., Yagita, H., Okumura, K., Ihara, A. Science (1992) [Pubmed]
  28. Update for the Canadian multicentre trial of cyclosporine in renal allografts. Stiller, C.R. N. Engl. J. Med. (1984) [Pubmed]
  29. Rapid loss of vertebral mineral density after renal transplantation. Julian, B.A., Laskow, D.A., Dubovsky, J., Dubovsky, E.V., Curtis, J.J., Quarles, L.D. N. Engl. J. Med. (1991) [Pubmed]
  30. Regulation of pro-opiomelanocortin biosynthesis and processing by transplantation immunity. Zakarian, S., Eleazar, M.S., Silvers, W.K. Nature (1989) [Pubmed]
  31. Azodicarbonamide inhibits T-cell responses in vitro and in vivo. Tassignon, J., Ismaili, J., Le Moine, A., Van Laethem, F., Leo, O., Vandevelde, M., Goldman, M. Nat. Med. (1999) [Pubmed]
  32. Arterial hypertension and renal allograft survival. Mange, K.C., Cizman, B., Joffe, M., Feldman, H.I. JAMA (2000) [Pubmed]
  33. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Lau, H.T., Yu, M., Fontana, A., Stoeckert, C.J. Science (1996) [Pubmed]
  34. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. Blair, P.J., Riley, J.L., Harlan, D.M., Abe, R., Tadaki, D.K., Hoffmann, S.C., White, L., Francomano, T., Perfetto, S.J., Kirk, A.D., June, C.H. J. Exp. Med. (2000) [Pubmed]
  35. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. Hancock, W.W., Lu, B., Gao, W., Csizmadia, V., Faia, K., King, J.A., Smiley, S.T., Ling, M., Gerard, N.P., Gerard, C. J. Exp. Med. (2000) [Pubmed]
  36. Donor-derived IP-10 initiates development of acute allograft rejection. Hancock, W.W., Gao, W., Csizmadia, V., Faia, K.L., Shemmeri, N., Luster, A.D. J. Exp. Med. (2001) [Pubmed]
  37. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. Lee, I., Wang, L., Wells, A.D., Dorf, M.E., Ozkaynak, E., Hancock, W.W. J. Exp. Med. (2005) [Pubmed]
  38. Cyclosporine: five years' experience in cadaveric renal transplantation. Merion, R.M., White, D.J., Thiru, S., Evans, D.B., Calne, R.Y. N. Engl. J. Med. (1984) [Pubmed]
  39. Effect of HLA typing and transfusions on cyclosporine-treated renal allograft recipients. Cats, S., Terasaki, P., Perdue, S., Mickey, M.R. N. Engl. J. Med. (1984) [Pubmed]
  40. Migration and maturation of Langerhans cells in skin transplants and explants. Larsen, C.P., Steinman, R.M., Witmer-Pack, M., Hankins, D.F., Morris, P.J., Austyn, J.M. J. Exp. Med. (1990) [Pubmed]
WikiGenes - Universities